Tamtam Try Tamtam free
Smith+Nephew logo

Smith+Nephew account plan

medical devices for mobility

At a glance

Smith+Nephew is a medical technology group in orthopaedics, sports medicine and wound care: $6,164m revenue in 2025 and 16,988 employees.

Smith+Nephew is a portfolio medical technology company focused on the repair, regeneration and replacement of soft and hard tissue, selling hip and knee implants, the CORI surgical robot, arthroscopic and ENT devices, and advanced wound care products to surgeons, hospitals and ambulatory surgery centers in around 100 countries. About 50% of revenue comes from the US and 20% from Europe, through a specialist sales force of 3,850+. In 2025 revenue was $6,164m (+5.3% underlying), trading profit $1,211m (19.7% margin) and free cash flow $840m; the group had 16,988 employees. Its CEO is Deepak Nath, its CFO John Rogers and its Chair Rupert Soames.

Business units

Strategic priorities

RISE strategy
Reach more patients (from more than 15 million to around 20 million in 2028), Innovate (more than 75 launches in five years), Scale through investment in Sports Medicine and Wound, and Execute efficiently.
2028 financial targets
6-7% organic revenue CAGR, 9-10% trading profit CAGR, free cash flow over $1 billion and 12-13% adjusted ROIC in 2028.
Fixing US knees and Orthopaedics margin
Fill the cementless gap with LANDMARK, expand CORI to hips (CORI Hip in Q1 2027), and lift the Orthopaedics trading margin by 300-400bps by 2028 and above 20% by 2030.
Market leadership in Sports Medicine and Wound
Prioritise investment in the higher growth and margin units, with the ambition to be "the number one Sports Medicine company in the world".
Cost efficiency and automation
Cumulative 12-Point Plan and zero-based budgeting savings reached $330m; 2026 savings are expected at around $200m, and a third wave aims to simplify and automate processes with new systems and AI, including a single global ERP.

Latest results

In Q3 2026 revenue was $1,551m, up 3.4% underlying, with Sports Medicine & ENT up 7.9%, Orthopaedics back to growth at 2.5% and Advanced Wound Management at -0.2%. Over nine months revenue was $4,648m (+2.7% underlying). H1 2026 trading profit was $566m (+8.1%), an 18.3% margin, and net debt $3,019m. On 4 November 2026 guidance was cut to around 3% underlying revenue growth, around 4% trading profit growth (around $1.25 billion), around $750m free cash flow and adjusted ROIC of around 9%, reflecting slower growth in US Orthopaedics.

Investments and deals

Integrity Orthopaedics acquisition
Acquired in January 2026 for $225m upfront plus up to $225m of performance payments over five years, adding TENDON SEAM rotator cuff repair.
Melton wound manufacturing site
A new wound plant at Melton near Hull, UK, due to start operations in 2027; capex rose $51m in H1 2026 for it and IT upgrades.
R&D and robotics
R&D of $296m in 2025, rising in 2026 to average over 5% of revenue; a five-year surgical robotics partnership with Imperial College London.
Inventory portfolio rationalisation
Phasing out 50 more product families, leaving 59 from 128, with an expected $500m reduction in capital employed; Orthopaedics manufacturing consolidated from eight core sites to three.
Share buyback
A $500m buyback announced on 6 May 2026, with $250m completed by the end of Q3.

Challenges and risks

US Orthopaedics weakness
US Knees fell 7.3% in Q3 2026, reflecting business lost in previous periods and the lack of a cementless offer across the installed base.
US skin-substitute reimbursement reset
Advanced Wound Bioactives declined as the market adapts more slowly than anticipated; the headwind is expected towards the upper end of the $20-40m range in 2026.
China Volume Based Procurement
China fell from about 7% of the business to around 2% by the end of 2025, and VBP is still expected in Arthroscopic Enabling Technologies and ENT.
Tariffs and pricing pressure
Tariffs, buying-group consolidation and commoditisation are named risks; the 2026 tariff impact of $60m is mostly offset by refunds.
Portfolio pressure
The Board approached Johnson & Johnson about a combination of Orthopaedics with DePuy Synthes; those talks ended and other strategic options are being explored.

What leadership says

“Orthopaedics is not where we want it to be, but we expect growth to accelerate as we fill portfolio gaps, starting later this year and continuing into 2027.”

Deepak Nath, Chief Executive Officer · Second Quarter and First Half 2026 Results, 4 August 2026

“Targets matter, targets are sacrosanct, and we're going to do everything in our power to meet the targets that our investors have signed on to”

Deepak Nath, Chief Executive Officer · Semafor, The Signal Interview, 5 June 2026

“There was a burning platform”

Deepak Nath, Chief Executive Officer · Semafor, The Signal Interview, 5 June 2026, on the 2022 starting point

“to fundamentally simplify and automate and streamline our processes”

John Rogers, Chief Financial Officer · Q2 2026 earnings call, 4 August 2026, on the third wave of cost work

Where a supplier can help

Process automation and ERP
The third wave of cost work and the single global ERP under RISE's Execute imperative open room for automation, AI and systems integration partners.
Commercial support for Sports Medicine and Wound growth
New headcount is going into front-line sales, medical education and customer service in these units: sales enablement, training and CRM tools fit this priority.
Manufacturing and supply chain
The Melton plant, site consolidation and inventory rationalisation call for equipment, construction, supply chain analytics and inventory tools.
Market access and reimbursement
The skin-substitute reset and payer prior authorisation for SANTYL make reimbursement analytics and market access services relevant to Advanced Wound Management.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Smith+Nephew?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Smith+Nephew

What does Smith+Nephew do?

It makes medical devices for the repair, regeneration and replacement of soft and hard tissue: orthopaedic implants and robotics, sports medicine and ENT devices, and advanced wound care products.

What is Smith+Nephew's revenue?

Revenue was $6,164m in 2025, up 5.3% underlying. For 2026 the company guides around 3% underlying growth.

How many employees does Smith+Nephew have?

16,988 employees in 2025.

What is Smith+Nephew's strategy?

RISE: reach more patients, innovate, scale Sports Medicine and Wound, and execute efficiently, targeting 6-7% organic revenue growth a year to 2028.

Who leads Smith+Nephew?

Deepak Nath is CEO, John Rogers CFO and Rupert Soames Chair.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)